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N 1851, Theodor Bilharz described a parasitic
infection (bilharzia) that would later be termed
schistosomiasis. Currently, 200 million people
in 74 countries have this disease; 120 million of
them have symptoms, and 20 million have severe ill-
ness.
 
1
 
 Schistosomiasis is caused by parasitic trema-
tode worms (schistosomes) that reside in the abdom-
inal veins of their vertebrate definitive hosts. The life
cycle of the schistosome is depicted in Figure 1. Schis-
tosomiasis is 1 of the 10 tropical diseases especially
targeted for control by the Special Program for Re-
search and Training in Tropical Diseases of the United
Nations Development Program, the World Bank, and
the World Health Organization.
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 The 54th World
Health Assembly has set a goal of treating annually
at least 75 percent of the school-age children who
are infected with schistosomes and soil-transmitted
helminths.
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Despite major advances in control and substantial
decreases in morbidity and mortality, schistosomiasis
continues to spread to new geographic areas.
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 Fur-
thermore, there are reports of resistance to praziquan-
tel, the mainstay of medical treatment. The majority
of 
 
Schistosoma haematobium,
 
 
 
S. mansoni, 
 
and 
 
S. in-
tercalatum
 
 infections are found in sub-Saharan Africa.
 
S. mansoni
 
 remains endemic in parts of Brazil, Vene-
zuela, and the Caribbean. 
 
S. japonicum
 
 infection still
occurs in China, Indonesia, and the Philippines, de-
spite substantial and largely successful control meas-
ures. 
 
S. mekongi
 
 is found in Cambodia and Laos,
I
 
along the Mekong River.
 
1
 
 Accurate figures on the
global status of schistosomiasis have been published
 
1
 
and are also available at http://www.who.int/ctd/
schisto/epidemio.htm.
Environmental changes that result from the devel-
opment of water resources and the growth and mi-
gration of populations can facilitate the spread of
schistosomiasis.
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 For example, the construction of
Diama Dam on the Senegal River led to the intro-
duction of 
 
S. mansoni
 
 into Mauritania and Senegal.
The movement of refugees and the displacement of
populations resulted in the introduction of 
 
S. man-
soni
 
 into Somalia and Djibouti. The presence of the
Aswan Dam in Egypt has led to the virtual elimina-
tion of 
 
S. haematobium
 
 from the Nile Delta but has
brought about the establishment of 
 
S. mansoni
 
 in up-
per Egypt. The Three Gorges Dam is currently being
built on China’s Yangtze River between two areas
where schistosomiasis is endemic.
 
7
 
 The Chinese Min-
istry of Health is currently evaluating the potential
effect of the dam on schistosomiasis transmission.
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Figure 1 (facing page).
 
 Life Cycle of the Schistosome.
Five species of schistosoma are known to infect humans. Infec-
tion with 
 
Schistosoma mansoni, S. japonicum, S. mekongi, 
 
or
 
S. intercalatum 
 
is associated with chronic hepatic and intestin-
al fibrosis. 
 
S. haematobium 
 
infection results in fibrosis, stric-
turing, and calcification of the urinary tract. All schistosoma in-
fections follow direct contact with fresh water that harbors
free-swimming larval forms of the parasite known as cercariae.
Cercariae penetrate the skin of humans or, in the case of
 
S. japonicum, 
 
humans and other mammalian hosts that act as
reservoirs for infection. The cercariae shed their bifurcated
tails, and the resulting schistosomula enter capillaries and lym-
phatic vessels en route to the lungs. After several days, the
worms migrate to the portal venous system, where they ma-
ture and unite. Pairs of worms then migrate to the superior mes-
enteric veins (in the case of 
 
S. mansoni
 
), the inferior mesenteric
and superior hemorrhoidal veins (in the case of 
 
S. japonicum
 
),
or the vesical plexus and veins draining the ureters (in the case
of 
 
S. haematobium
 
). Egg production commences four to six
weeks after infection and continues for the life of the worm —
usually three to five years. Eggs pass from the lumen of blood
vessels into adjacent tissues, and many then pass through the
intestinal or bladder mucosa and are shed in the feces (in the
case of 
 
S. mansoni 
 
and 
 
S. japonicum
 
) or urine (in the case of
 
S. haematobium
 
). The life cycle is completed when the eggs
hatch, releasing miracidia that, in turn, infect specific freshwa-
ter snails (
 
S. mansoni 
 
infects biomphalaria species, 
 
S. haema-
tobium 
 
infects bulinus species, and 
 
S. japonicum 
 
infects on-
comelania species). After two generations — primary and then
daughter sporocysts — within the snail, cercariae are released.
Modified from Jordan et al.
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 and Waine and McManus.
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PATHOPHYSIOLOGY AND CLINICAL 
DISEASE
 
Immediate Manifestations
 
A maculopapular eruption may arise at the site of
penetration by the cercarial (free-swimming larvae)
form of the parasite. In migrants or tourists who be-
come infected, skin reactions may develop within a
few hours after infection. However, a rash may ap-
pear up to one week later. The dermatitis is similar
to, but less severe than, swimmers’ itch, which de-
velops in sensitized persons when they are reinfected
by species of schistosomes that do not colonize hu-
mans (usually the types that colonize birds).
 
8
 
Acute Schistosomiasis
 
Acute schistosomiasis (Katayama fever)
 
9
 
 is com-
mon in areas of high transmission rates. A history of
contact with contaminated water 14 to 84 days be-
fore presentation is usual. Symptoms are thought to
be mediated by the immune complex, and the ma-
jority of cases begin with the deposition of an egg
into host tissues. Common symptoms include fever,
headache, generalized myalgias, right-upper-quadrant
pain, and bloody diarrhea. Respiratory symptoms have
been reported in up to 70 percent of persons infect-
ed with 
 
S. mansoni 
 
but less frequently in those in-
fected with 
 
S. haematobium.
 
10-12
 
 Tender hepatomeg-
aly is usually present, and splenomegaly occurs in one
third of cases. Aseptic meningitis is rare. There may
be radiologic evidence of interstitial pneumonitis. Not
all patients shed eggs, but all have eosinophilia and
most have positive serologic tests. Praziquantel works
exclusively against adult worms, and therefore, repeat-
ed treatment or a prolonged course with 20 mg per
kilogram of body weight per day has been used.
 
13,14
 
Oxamniquine has also been recommended.
 
Chronic Schistosomiasis
 
Gastrointestinal and Liver Disease
 
Schistosomiasis results from the host’s immune
response to schistosome eggs (Fig. 2) and the gran-
ulomatous reaction evoked by the antigens they se-
crete.
 
15
 
 The intensity and duration of infection deter-
mine the amount of antigen released and the severity
of chronic fibro-obstructive disease (Fig. 3). The
granulomas destroy the ova but result in fibrotic dep-
osition in host tissues. Most granulomas develop at the
sites of maximal accumulation of eggs — the intestine
and the liver (in the case of 
 
S. mansoni
 
 and 
 
S. japoni-
cum
 
) and the genitourinary tract (in the case of 
 
S. hae-
matobium
 
). However, periovular granulomas have
been found in many types of tissue, including the
skin, lung, brain, adrenal glands, and skeletal muscle.
 
16
 
The inflammatory response may assist the migration
of eggs into the lumen of the gut or urinary tract.
 
Figure 2.
 
 Morphology of the Eggs of the Three Key Schisto-
somes That Infect Humans.
The 
 
Schistosoma mansoni 
 
egg (Panel A, ¬200) measures ap-
proximately 140 by 61 µm and has a prominent lateral spine.
The 
 
S. haematobium 
 
egg (Panel B, ¬100) is approximately 150
by 62 µm with a prominent terminal spine. Both are ovoid. The
 
S. japonicum
 
 egg (Panel C, ¬200) is round, has a lateral spine
that is often obscured, and is smaller than the other two types
of eggs (60 by 100 µm).
A
B
C
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This possibility is supported by studies demonstrat-
ing that T-cell–deficient mice
 
17,18
 
 and patients with
advanced cases of the acquired immunodeficiency
syndrome have significantly reduced egg output.
 
19
 
Eggs retained in the gut wall induce inflammation,
hyperplasia, ulceration, microabscess formation, and
polyposis.
 
20-22
 
 Colicky hypogastric pain or pain in
the left iliac fossa is frequent. Diarrhea is common
and may alternate with constipation. Diarrhea is par-
ticularly common in children, and its presence cor-
relates strongly with schistosomiasis.
 
23
 
 Occult (or
sometimes visible) blood in the feces is usual. Severe
chronic intestinal disease may result in colonic or rec-
tal stenosis. Colonic polyposis may be manifested as a
protein-losing enteropathy.
 
24
 
 Inflammatory masses in
the colon may even mimic cancer.
 
25
 
 The relation be-
tween colorectal cancer and schistosomiasis has been
debated for decades. If there is an increase in the risk
of colorectal cancer, it is small.
 
14,26,27
 
Eggs of 
 
S. mansoni
 
 and 
 
S. japonicum
 
 embolize to
the liver, where the granulomatous inflammatory re-
sponse induces presinusoidal inflammation and peri-
portal fibrosis. Referred to as clay-pipe-stem fibrosis,
this condition occurs in 4 to 8 percent of patients
who have chronic infection.
 
16
 
 It takes many years to
develop and is associated with sustained heavy infec-
tion. Hepatomegaly reflects the presence of granulo-
matous inflammation and occurs early in the evolu-
tion of chronic disease.
 
28
 
 Periportal collagen deposits
lead to the progressive obstruction of blood flow,
portal hypertension, and ultimately varices, variceal
bleeding, splenomegaly, and hypersplenism. This peri-
portal fibrosis can be seen on ultrasonography, com-
puted tomography, or magnetic resonance imaging
and is characteristic of schistosomiasis. Hepatocellu-
lar synthetic function is preserved until the very late
stages of disease. Lobular architecture is retained,
and nodular regenerative hyperplasia does not occur.
Ultrasonography, in addition to clinical examination,
is used to detect and quantify hepatosplenic disease
on the basis of the criteria of the World Health Or-
ganization.
 
29-31
 
 
 
S. haematobium
 
 infection occasional-
ly causes mild colonic or hepatic disease.
 
32
 
Coinfection with either hepatitis B virus (HBV)
or hepatitis C virus (HCV) and 
 
S. mansoni
 
 is asso-
ciated with accelerated deterioration of hepatic func-
tion.
 
33,34
 
 Alcohol-induced cirrhosis, HBV, or HCV
can coexist with clay-pipe-stem fibrosis. The combi-
nation of chronic schistosomiasis caused by 
 
S. man-
soni
 
 and HBV infection may result in a higher risk
of hepatocellular carcinoma than that attributable to
HBV alone.
 
33
 
 In contrast, there does not appear to be
a significant interaction between HBV and 
 
S. japoni-
cum
 
 infection.
 
35
 
 Egypt’s mass campaigns of paren-
teral antischistosomal therapy (which ceased in the
1980s) contributed substantially to the high preva-
 
Figure 3.
 
 Clinical Findings in Two Patients Infected with Schis-
tosoma Species.
Panel A shows loose granuloma formation surrounding a
 
Schistosoma haematobium 
 
egg (arrow) in a bladder-biopsy
specimen from a 27-year-old man with hematuria and left-sid-
ed loin pain who had 
 
S. haematobium 
 
eggs in his urine (hema-
toxylin and eosin, ¬400). The black bar represents 100 µm. In
Panel B, a computed tomographic scan of the abdomen of the
same patient shows gross bilateral hydronephrosis (arrows)
due to ureteric stricturing. The right kidney is atrophic and non-
functional. In Panel C, an ultrasonogram shows gross hepatic
fibrosis (grade 3) (arrows) in a 45-year-old man with severe he-
patic schistosomiasis.
A
B
C
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lence of HCV infection in that country because of
the widespread reuse of needles.
 
36
 
Genitourinary Disease
 
Urinary tract disease is a specific trait of infection
with S. haematobium.32 Hematuria is the first sign of
established disease, appearing 10 to 12 weeks after
infection. Again, chronic disease is caused by gran-
ulomatous inflammation that occurs in response to
the deposition of eggs in tissue. Dysuria and hematu-
ria are common in both early and late disease. Late
manifestations also include proteinuria (often in the
nephrotic range), calcifications in the bladder, ob-
struction of the ureter, renal colic, hydronephrosis,
and renal failure. Secondary bacterial infection is fre-
quent. On cystoscopy, sandy patches (areas of rough-
ened bladder mucosa surrounding egg deposits) are
often visible and are pathognomonic. Structural ab-
normalities of the urinary tract can occur in children.37
The association between S. haematobium infection
and squamous-cell carcinoma of the bladder has been
the subject of intense research and debate. Squa-
mous-cell carcinomas of the bladder associated with
S. haematobium tend to be well differentiated and to
metastasize locally. In Egypt, squamous-cell carcino-
ma of the bladder accounts for 18 to 28 percent of
all cancers, with an incidence of 10.8 per 100,000
population.38,39 Male smokers appear to be at partic-
ular risk.39 The association appears to be consistent in
many sub-Saharan nations as well.32 However, large
autopsy series have failed to demonstrate a consistent
association with a particular type of tumor,40 and
squamous-cell carcinoma of the bladder is prevalent
in some countries that have a very low prevalence of
S. haematobium infection or none at all. S. haematobi-
um–associated bladder cancers are often associated
with mutations of the p53 and cyclin-dependent–
kinase inhibitor 2 tumor-suppressor genes.32 At pres-
ent, there is sufficient evidence to conclude that S. hae-
matobium has a role in causing some types of blad-
der cancer.
S. haematobium infection causes genital disease in
approximately one third of infected women.32,41 Iso-
lated internal genital disease is less frequent. Vulval
and perineal disease may be hypertrophic, ulcerative,
fistulous, or wart-like and may be mistaken for other
genital infections, particularly condylomata lata.42 Tub-
al infertility may be a late complication. Vulval schis-
tosomiasis may also facilitate the transmission of hu-
man immunodeficiency virus (HIV).41,43
Neurologic and Other Manifestations
Symptoms do not develop in all persons with egg
deposits in the central nervous system. The mecha-
nism of egg deposition is unknown. The presence of
egg deposits may reflect either aberrant migration of
worms or the embolization of eggs from a remote
location.8 Central nervous system schistosomiasis
has been described in soldiers and aid workers serv-
ing in areas where schistosomiasis is endemic44,45 and
in tourists who have had relatively limited exposure
to such areas. Focal or generalized tonic–clonic ep-
ilepsy is a typical presentation for S. japonicum infec-
tion with central nervous system involvement. Focal
neurologic deficits may also occur.46 Among groups
of Chinese adults hospitalized with schistosomiasis,
up to 4.3 percent have central nervous system dis-
ease.14 The prevalence of epilepsy in communities
where infections have occurred has been estimated at
1 to 4 percent — eight times as high as at base line.14,45
Transverse myelitis is the most common neurologic
manifestation of S. mansoni or S. haematobium infec-
tion. Treatment is largely supportive. Praziquantel is
usually used, augmented by a course of corticoster-
oids and anticonvulsants. Lifelong use of anticonvul-
sants is rarely indicated.
Schistosome infection during childhood causes sub-
stantial growth retardation and anemia.28,47,48 Success-
ful chemotherapy leads to substantial but incomplete
catch-up growth and improvement in hemoglobin
levels. Infected children may also have cognitive im-
pairment and memory deficits.49 Schistosome infec-
tion appears to have adverse effects on both mater-
nal health and the fetus. Unfortunately, praziquantel
is listed in pregnancy category B (safe in animals but
untested in humans). Many experts believe the risk–
benefit ratio favors treatment, at least after the fourth
month of gestation.
Infections in Travelers and Immigrants
Acute schistosomiasis is a problem for travelers,
particularly those who visit Africa.50 Swimming in
Lake Malawi, Lake Kariba, and the Zambezi River
has been particularly problematic. Hematuria and
diarrhea are common early symptoms. Central nerv-
ous system disease, including transverse myelitis, is
rare. Standard doses of praziquantel are curative. Al-
though the average life span of a schistosome is five
years, adult worms may live for decades. Immigrants
from areas where schistosoma species are endemic
can remain infected for 30 to 40 years.51 Urinary
schistosomiasis can be misdiagnosed as bladder can-
cer or chronic prostatitis. Hepatic or intestinal disease
may be found in patients who present with anemia
and chronic gastrointestinal bleeding. Schistosomia-
sis is not a notifiable disease in the United States or
in many other developed countries, so there is no ac-
curate information about infection rates among re-
turned travelers and immigrants.
Susceptibility
HLA class I and class II antigens are associated
with more severe manifestations of disease. For ex-
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ample, HLA-B16 and Cw2 have been associated
with S. haematobium–related bladder cancer among
patients in Egypt.52 HLA-DR and DQ alleles are as-
sociated with some protection against mild liver fi-
brosis, and some HLA-DP alleles are associated with
protection against severe hepatic fibrosis.53 Advanced
hepatic fibrosis appears to be closely linked to the
interferon-g–receptor gene on chromosome 6q22–
q23.54 Another locus (SM1) is associated with resist-
ance to reinfection with S. mansoni and is located on
chromosome 5q31–q33.55 A gene product of this
locus may regulate the development of type 2 helper
T cells.
DIAGNOSIS
The detection of schistosome eggs in feces or
urine is diagnostic of schistosomiasis. The extent of
shedding of eggs may fluctuate widely, and as many
as three specimens may be required in some patients.
S. mansoni or S. japonicum eggs may be observed in
stool specimens of 2 to 10 mg with or without sus-
pension in saline. The use of formalin-based tech-
niques for sedimentation and concentration may in-
crease the diagnostic yield.56 Such techniques are
useful in patients with few eggs, as in a returned
traveler. The miracidium-hatching test has been used
extensively by public health workers in China to rule
out S. japonicum infection.40 The test is initiated by
the concentration of ova from feces through a nylon
tissue bag and suspension in distilled water. Miracidia
that hatch from ova are visualized microscopically, and
their presence is diagnostic of infection. In patients
with a typical clinical presentation but negative urine
and feces specimens, a biopsy of bladder or rectal mu-
cosa must be used for diagnosis. These are the most
sensitive diagnostic procedures available.
The rapid, simple, and inexpensive Kato–Katz thick-
smear stool examination requires 40 to 50 mg of fe-
ces and is widely used in field studies57 and national
control programs to determine the burden of eggs
in feces. Several population-based studies have dem-
onstrated that mean egg burdens correlate with the
mean severity of disease.58,59 However, it is generally
unnecessary to quantify the egg burden in order to
provide clinical care.
Antibody detection is useful in a few specific cir-
cumstances, but its use is limited because antibodies
persist after parasitologic cure. A positive serologic
test may be diagnostic in patients in whom there are
no eggs, such as those with Katayama fever. Further-
more, serologic testing is useful in field studies for
defining regions of low-level endemicity where indi-
vidual patients have low egg burdens.60,61 Serologic
testing may also be useful in determining whether
infection has reemerged in a region after an apparent-
ly successful eradication program. Commercially avail-
able immunodiagnostic kits are not as sensitive as
multiple fecal examinations and are less specific.62 De-
tection of circulating adult-worm and egg antigens
is a promising technique that may eventually super-
sede traditional diagnostic methods. A recent devel-
opment is an immunoblot assay for the detection of
adult-worm antigen,63 which reportedly has 95 per-
cent sensitivity and 100 percent specificity.
Additional supportive laboratory evidence of schis-
tosomiasis might include evidence of peripheral-blood
eosinophilia, anemia (iron-deficiency anemia, anemia
of chronic disease, or macrocytic anemia), hypoalbu-
minemia, elevated urea and creatinine levels, and hy-
pergammaglobulinemia. Splenomegaly develops in
some patients with pancytopenia.
Biochemical markers of hepatic fibrosis are cur-
rently a focus of research. Serum levels of procol-
lagen peptide (types III and IV), the P1 fragment of
laminin, hyaluronic acid, and fibrosin may be elevat-
ed in patients with severe hepatic fibrosis and can
decrease after praziquantel treatment.59,64,65 Persistent
elevation of these levels after parasitologic cure sug-
gests the presence of coinfection with HBV or HCV.
The measurement of the N-terminal propeptide of
type III procollagen, combined with the C-terminal
propeptide of type IV procollagen and collagen VI,
can be used to predict the risk of progressive hepatic
fibrosis. A biopsy of the liver may be necessary in
some patients with coinfection. Liver involvement in
patients with schistosomiasis is often suggested by
the characteristic appearance of the organ on abdom-
inal imaging.
TREATMENT AND CHEMOPROPHYLAXIS
Praziquantel, a pyrazinoisoquinoline derivative, is
the mainstay of treatment and a critical part of com-
munity-based schistosomiasis control programs. Since
its discovery in the mid-1970s,66 its safety and effi-
cacy have ensured its widespread use. It is absorbed
well but undergoes extensive first-pass hepatic clear-
ance. Praziquantel is secreted in breast milk, it is me-
tabolized by the liver, and its (inactive) metabolites
are excreted in the urine. The drug’s precise action
on adult worms is unknown. It appears to cause te-
tanic contractions and tegumental vacuoles, causing
worms to detach from the wall of the vein and die.
In animal models, the presence of host antibodies has
been shown to be critical for its efficacy.67 Optimal
therapy requires two to three doses of 20 mg per kil-
ogram given six to eight hours apart with food. Com-
munity-based control programs usually treat patients
with a single dose of 40 mg per kilogram. Higher
doses are often used against S. japonicum (a total dose
of 60 mg per kilogram). Reexamination of feces or
urine one month after treatment is recommended in
order to assess efficacy.
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Praziquantel reliably cures 60 to 90 percent of pa-
tients and substantially decreases the worm burden
and egg production in those who are not cured. Pa-
tients who continue to shed viable eggs should be
re-treated with the same dose; the second treatment
is usually successful. Hepatic fibrosis from S. mansoni
infection68,69 and S. japonicum infection31,68 and the
urinary tract disease from S. haematobium infection37,68
may improve after successful treatment if reinfection
is avoided. The efficacy of praziquantel is unaltered
in patients who are coinfected with HIV type 1
(HIV-1).70 Treatment of schistosomiasis caused by
S. mansoni does not influence the load of HIV-1.71
Corticosteroids may be useful adjuvant treatment for
cerebral disease associated with features of surround-
ing edema apparent on radiology46 or for severe Ka-
tayama fever. Oxamniquine is the only alternative to
praziquantel for S. mansoni infection but has limited
availability. Metrifonate is an alternative drug for S. hae-
matobium infection but is no longer available commer-
cially. We believe that these drugs should be main-
tained in international formularies in case widespread
resistance to praziquantel emerges.
Praziquantel is a poor choice for chemoprophy-
laxis because of its short half-life (1 to 1.5 hours)
and because it cannot kill schistosomula (the migrat-
ing larvae) that are 3 to 21 days old. Artemether,
which is well known for its antimalarial activity, does
kill schistosomula during the first 21 days in the
body. Therefore, it should kill all immature schisto-
somula if it is given every two weeks.72 In a trial in-
volving residents of an area in southern China where
S. japonicum is endemic, the drug was administered
every 15 days throughout the transmission season at
a dose of 6 mg per kilogram.72 Acute cases were pre-
vented and new infections were less than half as fre-
quent as in the control group, and those that did occur
were of lower intensity. Artemether is also active
against the other schistosome species that infect hu-
mans.73-75 Combining artemether with praziquantel
appears to produce a synergistic killing of adult
worms.76 The prospects seem good for prophylaxis
with artemether in high-risk groups in areas where
schistosomiasis is endemic, such as flood relief work-
ers, tourists, and fishermen.73 The doses required are
lower than those required for treatment of malaria,
but it is unlikely that artemether would be used in
areas where malaria is endemic because such use might
lead to the selection of artemether-resistant Plasmo-
dium falciparum.
Resistance to praziquantel may be emerging after
nearly 20 years of intensive use. Hycanthone resist-
ance in S. mansoni is well documented.77 In regions
of Egypt and Kenya where there has been heavy ex-
posure to praziquantel, there are reports of S. man-
soni and S. haematobium infections that are not re-
sponsive to multiple courses of treatment.78,79 There
is some laboratory evidence suggesting that these
drug-tolerant worms may have altered tegumental
architecture, which could limit the effectiveness of
the drug.78 So far, however, patients in many com-
munities have undergone multiple courses of treat-
ment over a period of 10 or more years without a
demonstrable loss of efficacy.80 Because worm repro-
duction in the mammalian host is sexual and the
generation time is relatively long, resistance is likely
to take many years to become an important clinical
and public health issue.80
VACCINE DEVELOPMENT
The control of schistosomiasis requires large-scale
population-based chemotherapy in addition to envi-
ronmental and behavioral modification. It is difficult
and costly to sustain such a program.4 There is a
need for a vaccine for long-term prevention. Schis-
tosomula appear to be the primary source of the tar-
get antigens that are vaccine candidates. A high level
of protection against S. mansoni infection has been
attained in mice and a similar level of protection
against S. japonicum infection has been attained in
mice, buffaloes, and pigs when the animals were im-
munized with irradiated cercariae. Both type 1 and
type 2 helper-T-cell responses may contribute to pro-
tection.81
Considerable efforts have been made to identify
relevant schistosome antigens that may be involved in
inducing protective immune responses, with a view to
developing a recombinant-protein, synthetic-peptide,
or DNA vaccine.81 Coordinated laboratory and field
research has identified a set of well-defined S. man-
soni molecules with protective potential.81 In recent
phase 1 and 2 clinical trials involving human volun-
teers, a schistosome-derived molecule, the S. haema-
tobium glutathione S-transferase (Sh28GST) (Bilhvax),
was safe and demonstrated excellent immunogenici-
ty.82 In addition, recent studies in water buffaloes of
the protection afforded by the S. japonicum antigens
paramyosin (Sj-97) and GST-26 (Sj-GST26) have
yielded encouraging results, and it may be feasible to
develop a vaccine that blocks transmission for use in
reservoir hosts.62 Given the breadth of the interna-
tional efforts to generate antischistosome vaccines,
there is considerable optimism about possible future
success.83 However, these vaccines will be only one
component of schistosomiasis control programs. En-
vironmental modification of snail habitats and use of
molluscicides are common methods of controlling
the parasite but are expensive.
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